City of Hope researcher awarded Prostate Cancer Foundation’s Young Investigator Award
December 16, 2015

Contact
Media Relations
800-888-5323
[email protected]

DUARTE, Calif. — The development of a highly-specific type of immunotherapy, known as CAR-T cell therapy, could lead to a new type of treatment for advanced prostate cancer. Saul Priceman, Ph.D., an assistant research professor at City of Hope, is working to create such a treatment, and his work recently received a boost from the Prostate Cancer Foundation (PCF).

Priceman was one of 19 researchers worldwide to receive a PCF Young Investigator Award. Each award is for $225,000. Recipients, who are exceptional early career scientists that have demonstrated potential for high-impact research to improve the lives of men with prostate cancer in the near future, were selected from a pool of 107 applicants from 65 institutions in nine countries.

“This award will allow our research team to develop new immunotherapy treatments for advanced prostate cancer that are resistant to chemotherapy,” Priceman said. “We are honored that our work has been recognized among so many worthy research projects.”

Priceman’s research focuses on stimulating a patient’s immune response by engineering T cells, a specialized immune cell, to express chimeric antigen receptors (CAR) that allow the cells to recognize, bind to and eliminate a tumor. Priceman will use a novel genetically modified CAR-T cell to seek out and kill prostate cancer cells. The research could lead to a new clinical trial for advanced prostate cancer.

Since 2008, PCF’s Young Investigator Program has made three-year investments in highly-skilled individuals with the expertise to rapidly translate the latest scientific discoveries from bench to bedside. Awardees are also mentored by leaders in prostate cancer research.

Prostate cancer will affect one in seven men in his lifetime, and recent studies have indicated certain genetic similarities with breast, pancreatic and colon cancer. This means that research in prostate cancer is extraordinarily scalable with the potential for new lifesaving treatments for other cancers.

For more information about City of Hope, visit www.cityofhope.org or follow City of Hope on facebook, twitter, youtube or flickr.

About City of Hope

City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope’s main hospital is located in Duarte, California, just northeast of Los Angeles, with clinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics.

About the Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization funding and accelerating prostate cancer research. Founded in 1993, PCF has raised more than $634 million and provided funding to more than 2,000 research programs at nearly 200 cancer centers and universities. The PCF global research enterprise now extends to 19 countries. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer. For more information, click here.

 

 

# # #